Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARA NASDAQ:ENDP NASDAQ:PMVP NASDAQ:ZEAL NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsENDPEndo International$0.45$0.28▼$7.07$141K1.1528.19 million shs9,967 shsPMVPPMV Pharmaceuticals$1.53+4.1%$1.41$0.81▼$1.84$77.90M1.51626,892 shs655,038 shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/AZYMEZymeworks$17.93-2.1%$15.97$9.03▼$19.50$1.38B1.51546,377 shs613,021 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+66.92%ENDPEndo International0.00%0.00%0.00%0.00%0.00%PMVPPMV Pharmaceuticals+4.08%+7.75%+16.79%+13.33%-3.77%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%ZYMEZymeworks-2.13%-1.65%+10.34%+25.47%+36.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsENDPEndo International$0.45$0.28▼$7.07$141K1.1528.19 million shs9,967 shsPMVPPMV Pharmaceuticals$1.53+4.1%$1.41$0.81▼$1.84$77.90M1.51626,892 shs655,038 shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/AZYMEZymeworks$17.93-2.1%$15.97$9.03▼$19.50$1.38B1.51546,377 shs613,021 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+66.92%ENDPEndo International0.00%0.00%0.00%0.00%0.00%PMVPPMV Pharmaceuticals+4.08%+7.75%+16.79%+13.33%-3.77%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%ZYMEZymeworks-2.13%-1.65%+10.34%+25.47%+36.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/AENDPEndo International 0.00N/AN/AN/APMVPPMV Pharmaceuticals 2.33Hold$5.50259.48% UpsideZEALZealand Pharma A/S 0.00N/AN/AN/AZYMEZymeworks 3.00Buy$24.7538.04% UpsideCurrent Analyst Ratings BreakdownLatest CARA, ZYME, ENDP, ZEAL, and PMVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025ZYMEZymeworksJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $23.0010/14/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Buy$13.00 ➝ $26.0010/14/2025PMVPPMV PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/10/2025ZYMEZymeworksB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.009/27/2025PMVPPMV PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $22.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00ENDPEndo International$2.99B0.00N/A0.06($13.60) per share0.00PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/AZEALZealand Pharma A/S$46.54M17.59N/AN/A$3.38 per share5.20ZYMEZymeworks$122.87M10.97N/AN/A$6.63 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/AENDPEndo International-$613.24M-$11.07N/A0.00N/A-93.31%-34.25%6.72%N/APMVPPMV Pharmaceuticals-$58.71M-$1.57N/AN/AN/AN/A-47.94%-43.82%11/6/2025 (Estimated)ZEALZealand Pharma A/S-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/AZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%11/6/2025 (Estimated)Latest CARA, ZYME, ENDP, ZEAL, and PMVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025PMVPPMV Pharmaceuticals-$0.40N/AN/AN/AN/AN/A11/6/2025N/AZYMEZymeworks-$0.28N/AN/AN/A$33.69 millionN/A8/7/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39-$0.41-$0.02-$0.41N/AN/A8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AENDPEndo InternationalN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/AZEALZealand Pharma A/SN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71ENDPEndo InternationalN/A1.861.62PMVPPMV PharmaceuticalsN/A12.5212.52ZEALZealand Pharma A/S0.934.794.78ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%ENDPEndo International80.39%PMVPPMV Pharmaceuticals90.20%ZEALZealand Pharma A/S1.73%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%ENDPEndo International1.20%PMVPPMV Pharmaceuticals7.60%ZEALZealand Pharma A/S2.20%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableENDPEndo International3,103235.14 million232.32 millionNo DataPMVPPMV Pharmaceuticals5052.99 million48.96 millionOptionableZEALZealand Pharma A/S35546.54 million45.51 millionNot OptionableZYMEZymeworks46075.17 million67.56 millionOptionableCARA, ZYME, ENDP, ZEAL, and PMVP HeadlinesRecent News About These CompaniesRitholtz Wealth Management Has $317,000 Stake in Zymeworks Inc. $ZYMEOctober 21 at 3:56 AM | marketbeat.comZymeworks (NYSE:ZYME) Price Target Raised to $23.00October 19 at 2:57 AM | americanbankingnews.comJPMorgan ups Zymeworks target, places on ‘Positive Catalyst Watch’October 16, 2025 | msn.comWall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to TradeOctober 16, 2025 | zacks.comJPMorgan Chase & Co. Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock PriceOctober 16, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Zymeworks Q3 Earnings?October 16, 2025 | marketbeat.comZymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025October 16, 2025 | globenewswire.comHC Wainwright & Co. Upgrades Zymeworks (ZYME)October 14, 2025 | msn.comZymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy?October 14, 2025 | zacks.comZymeworks (NYSE:ZYME) Shares Gap Up - Here's WhyOctober 14, 2025 | marketbeat.comZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International ConferenceOctober 13, 2025 | tmcnet.comZymeworks Inc.: Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International ...October 13, 2025 | finanznachrichten.deZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International ConferenceOctober 13, 2025 | globenewswire.comZymeworks (NYSE:ZYME) Stock Price Up 7.2% - Here's What HappenedOctober 11, 2025 | marketbeat.comEquities Analysts Set Expectations for Zymeworks Q3 EarningsOctober 11, 2025 | americanbankingnews.comLifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME)October 10, 2025 | marketbeat.comZymeworks appoints Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | msn.comInMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of DirectorsOctober 9, 2025 | newsfilecorp.comNZymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | globenewswire.comWhy Analysts See the Zymeworks Story Evolving After Key Pipeline and Market MovesOctober 8, 2025 | finance.yahoo.comQ1 Earnings Forecast for Zymeworks Issued By Lifesci CapitalOctober 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCARA, ZYME, ENDP, ZEAL, and PMVP Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Endo International NASDAQ:ENDPEndo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.PMV Pharmaceuticals NASDAQ:PMVP$1.53 +0.06 (+4.08%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$1.52 -0.02 (-0.98%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Zealand Pharma A/S NASDAQ:ZEALZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Zymeworks NYSE:ZYME$17.93 -0.39 (-2.13%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$17.93 0.00 (0.00%) As of 08:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
